In March last year, the CCDI Molecular Characterization Initiative (MCI) launched. Since then, it has opened enrollment to children, adolescents, and young adults newly diagnosed with central nervous system tumors, soft tissue sarcomas, and rare tumors—with plans to expand. Results have been returned to more than 750 participants.
Data released from the initiative are searchable through the database of Genotypes and Phenotypes and Seven Bridges’ Cancer Genomics Cloud. See Where Can These Data Be Accessed? on the MCI web page for more information about access.
Enrollment continues and participation is free. Potential participants must also be receiving care from a Children’s Oncology Group–affiliated hospital.